6533b833fe1ef96bd129b71f
RESEARCH PRODUCT
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma
Maria-elisabeth GoebelerNicholas J. MorleyRalf C. BargouAlicia ZhangJanet FranklinLuke CoyleKarim IskanderAndreas ViardotGeorg HessGiuseppe GrittiDavid Cohansubject
OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicineAntibodies BispecificmedicineHumansComplete responsebusiness.industryLymphoma Non-HodgkinHematologymedicine.diseaseLymphomaOncology030220 oncology & carcinogenesisRelapsed refractoryBlinatumomabLymphoma Large B-Cell DiffuseNeoplasm Recurrence LocalbusinessDiffuse large B-cell lymphoma030215 immunologymedicine.drugdescription
Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...
year | journal | country | edition | language |
---|---|---|---|---|
2020-07-07 | Leukemia & Lymphoma |